Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
This study's findings support the potential of a daily 2000 mg EPA as a prophylactic pharmacotherapy in chronic migraine management, specifically in mitigating migraine attacks, migraine headache days, and overall quality of life.
Authors
- Hadi Esmaily (ORCID: https://orcid.org/0000-0001-6915-6028)
- Mohsen Koosha (ORCID: https://orcid.org/0000-0002-1660-3178)
- Ghader Mohammadnezhad (ORCID: https://orcid.org/0000-0001-5300-349X)
- Farhad Assarzadegan (ORCID: https://orcid.org/0000-0002-3628-619X)
Institutions
- Iran University of Medical Sciences (IR)
- Imam Hossein Hospital (IR)
- Shahid Beheshti University of Medical Sciences (IR)
Publication Details
- Journal
- Headache The Journal of Head and Face Pain
- Published
- 2024-09-02
- DOI
- https://doi.org/10.1111/head.14808
- Citations
- 3
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.16